Can we ever observe newly diagnosed chronic phase CML patients and not immediately start them on therapy?

I can't think of a situation that would justify a "watch and wait" approach to CML. There are a number of effective therapies. Even if a patient has side effects from one TKI, there are others to choose from. What justification is there for not using an effective therapy? What is the rationale?

Da...

It’s a reasonable question if the patient has a low life expectancy give age or other comorbidities. Before the clinical development of imatinib, median overall survival was on the order of 4 years. These factors can be taken into context, but otherwise, the natural history of the disease with its e...